OVARIAN Non-commercial trials
Trial Study description Status
HE4-FU-OVCA/
CEEGOG OX-01
documents available here
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
A prospective multicentre observational study
The target size of the group: 150 patients
Ongoing
ATALANTE/
ENGOT-ov29/GINECO
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab
The target size of the group: 600 patients
Enrollment closed
EXPRESSION VI/
ENGOT-ov40/NOGGO S13
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer
The target size of the group: 100-200 per participating country
Ongoing
MITO33/
ENGOT-ov51
A Randomized phase III trial on Niraparib-TSR 042 vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment
The target size of the group: 427
Under preparation

 

 

CERVICAL Non-commercial trials
Trial Study description Status
SENTIX/
CEEGOG CX-01/
ENGOT-cx2
documents available here
Sentinel node in cervix cancer
A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer
The target size of the SLN Study group: 600 patients
The target size of the Control group: 100 patients
Estimated enrollment period: 2016 – 2020
Ongoing
FERTISS/
CEEGOG CX-03
documents available here
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials Ongoing
CERVANTES/
CEEGOG CX-05
A prospective randomized trial on the role of radical surgery and adjuvant therapy in the management of intermediate risk cervical cancer patients.
The target size of the group: TBD
Under preparation
RSS-EAC-PAT/
CEEGOG CX-04
documents available here
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes  Closed
ABRAX/
CEEGOG CX2/
ENGOT-cx3
documents available here
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity Closed
SALVAGE/
CEEGOG EX01
A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer
Salvage database – data from 620 patients collected, currently results analysed
Closed

 

 

ENDOMETRIAL Non-commercial trials
Trial Study description Status
TESLA1/
CEEGOG EX-02
Tracers for Endometrial cancer Sentinel node LAbelling
A Prospective observational study on sentinel node biopsy using two concurrent labelling techniques (radioactive tracer with/without blue dye vs. indocyanin green-ICG) in early-stage endometrial cancer patients
The target size of the group: 92 patients
Under preparation
ENGOT-EN2-DGCG/
EORTC 55102
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer
The target size of the group: 240 patients
Enrollment closed

 

 

OVARIAN Commercial trials
Trial Study description Status
MK-7339-001-00/
ENGOT-ov43/BGOG
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
The target size of the group: 1086 patients
Ongoing
INNOVATE-3/
ENGOT-ov50/BGOG
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant  ovarian cancer (PROC)
The target size of the group: 540 patients
Ongoing
FIRST
ENGOT-ov44/GINECO
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy
The target size of the group: 720 - 960 patients
Ongoing
ATHENA/
ENGOT-ov45/NCRI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
The target size of the group: 1000 patients
Ongoing
MIRASOL/
ENGOT-ov55/ BGOG
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
The target size of the group: 430 patients
Under preparation
SOV09/VITALIA/
ENGOT-ov53/CEEGOG
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma
The target size of the group: 678 patients
Under preparation
SOTIO/
SOV01
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma
The target size of the group: additional 30 patients
Enrollment closed
SOTIO/
SOV06
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma
The target size of the group: 30 patients
Enrollment closed
IMAGYN050/
YO39523/GOG-3015/
ENGOT-ov39
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
The target size of the group: 1300 patients
Enrollment closed
PRIMA/
ENGOT-ov26/GEICO/1509
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
The target size of the group: 620 patients
Enrollment closed
JAVELIN OVARIAN 200 A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer
Approximately 550 patients will be randomized
Enrollment closed
SOTIO/
SOV02
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma Closed
SOTIO/
SOV03
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma Closed
MILO/
ENGOT-ov11/BGOG
MEK Inhibitor in Low-grade Serous Ovarian Cancer
A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Closed
NOVA/
ENGOT-ov16/NSGO
Niraparib in OVArian cancer
A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer
Closed

 

 

CERVICAL Commercial trials
Trial Study description Status
GCT1015-05/
ENGOT-cx8/BGOG
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer
The target size of the group: 140 patients
Ongoing
GCT1015-07/
ENGOT-cx12/BGOG
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer
The target size of the group: 486 patients
Under preparation
FERMATA/
ENGOTcx13/AGO
An International Randomized Double-blind Clinical Trial of BCD-100
Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer
The target size of the group: 316 patients
Under preparation
KEYNOTE-A18/
ENGOT-cx11/MITO
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
The target size of the group: 980 patients
Under preparation
GCT1015-04/
ENGOT-cx6/BGOG
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer
The target size of the group: 100 patients
Enrollment closed

 

 

ENDOMETRIAL Commercial trials
Trial Study description Status
SIENDO/
ENGOT-EN5/BGOG-EN5
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer.
The target size of the group: 192 patients
Ongoing
RUBY/
ENGOT EN-6/NSGO
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)
The target size of the group: 470 patients
Ongoing